ES2193601T3 - Utilizacion de peptidos de citrulina derivados a la filagrina en el marco del tratamiento de enfermedades autoinmunes. - Google Patents

Utilizacion de peptidos de citrulina derivados a la filagrina en el marco del tratamiento de enfermedades autoinmunes.

Info

Publication number
ES2193601T3
ES2193601T3 ES98964537T ES98964537T ES2193601T3 ES 2193601 T3 ES2193601 T3 ES 2193601T3 ES 98964537 T ES98964537 T ES 98964537T ES 98964537 T ES98964537 T ES 98964537T ES 2193601 T3 ES2193601 T3 ES 2193601T3
Authority
ES
Spain
Prior art keywords
filagrine
citruline
framework
treatment
autoimmune diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98964537T
Other languages
English (en)
Inventor
Guy Serre
Elisabeth Girbal-Neuhauser
Christian Vincent
Michel Simon
Mireille Sebbag
Pascal Dalbon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite de Toulouse
Original Assignee
Universite Toulouse III Paul Sabatier
Universite de Toulouse
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite Toulouse III Paul Sabatier, Universite de Toulouse filed Critical Universite Toulouse III Paul Sabatier
Application granted granted Critical
Publication of ES2193601T3 publication Critical patent/ES2193601T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Rehabilitation Therapy (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Utilización de un antígeno peptídico reconocido específicamente por los autoanticuerpos antifilagrina presentes en el suero de pacientes que padecen poliartritis reumatoide, constituido por un péptido que comprende la unidad tripeptídica Ser-Cit-His, en la que Cit representa un residuo de citrulina, el cual se deriva de toda o de parte de la secuencia de una unidad de filagrina por sustitución de la menos un residuo de arginina por un residuo de citrulina, para la obtención de un medicamento destinado al tratamiento de una patología que implica una respuesta autoinmune respecto de epitopes de citrulina reconocidos por dichos anticuerpos antifilagrina, con la excepción de la utilización de un péptido de secuencia: Gln Gly Ser Cit His Gln Gln Ala Arg.
ES98964537T 1997-12-30 1998-12-29 Utilizacion de peptidos de citrulina derivados a la filagrina en el marco del tratamiento de enfermedades autoinmunes. Expired - Lifetime ES2193601T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9716672A FR2773078B1 (fr) 1997-12-30 1997-12-30 Utilisation de peptides citrullines derives de la filaggrine pour le traitement de la polyarthrite rhumatoide

Publications (1)

Publication Number Publication Date
ES2193601T3 true ES2193601T3 (es) 2003-11-01

Family

ID=9515271

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98964537T Expired - Lifetime ES2193601T3 (es) 1997-12-30 1998-12-29 Utilizacion de peptidos de citrulina derivados a la filagrina en el marco del tratamiento de enfermedades autoinmunes.

Country Status (10)

Country Link
EP (1) EP1041997B1 (es)
JP (1) JP4557421B2 (es)
AT (1) ATE237345T1 (es)
AU (1) AU1971899A (es)
CA (1) CA2315294C (es)
DE (1) DE69813620T2 (es)
DK (1) DK1041997T3 (es)
ES (1) ES2193601T3 (es)
FR (1) FR2773078B1 (es)
WO (1) WO1999034819A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2900657B1 (fr) 2006-05-03 2009-04-17 Univ Toulouse Identification de modulateurs de l'activation des macrophages, utilisables pour le traitement de la polyarthrite rhumatoide
FR2908134B1 (fr) * 2007-12-04 2012-10-12 Univ Toulouse 3 Paul Sabatier Identification de modulateurs de l'activation des macrophages, utilisables pour le traitement de la polyarthrite rhumatoide

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7259691A (en) * 1990-01-31 1991-08-21 Board Of Regents Of The University Of Oklahoma, The Assays and treatments for autoimmune diseases
DE511116T1 (de) * 1991-04-26 1993-04-29 Clonatec S.A., Paris Antigene, die von polyarthritis rheumatoide antikoerpern erkannt werden, ihre herstellung und ihre anwendungen.
AU6098994A (en) * 1993-01-27 1994-08-15 Duke University Methods and agents for the diagnosis and treatment of rheumatoid arthritis
FR2752842B1 (fr) * 1996-08-30 1998-11-06 Biomerieux Sa Antigenes derives des filaggrines et leur utilisation pour le diagnostic de la polyarthrite rhumatoide
NL1004539C2 (nl) * 1996-11-15 1998-05-20 Stichting Tech Wetenschapp Peptide afgeleid van een door auto-antilichamen van patiënten met reumatoïde artritis herkend antigeen, antilichaam daartegen en werkwijze voor het detecteren van auto-immuunantilichamen.
CZ20001963A3 (cs) * 1997-11-28 2002-04-17 Innogenetics N. V. Peptidy obsahující citrulin rozeznaný sérem revmatické artritidy jako prostředky pro diagnózu a léčbu
FR2773157B1 (fr) * 1997-12-30 2001-10-05 Bio Merieux Epitopes peptidiques reconnus par des auto-anticorps antifilaggrine presents dans le serum des patients atteints de polyarthrite rhumatoide

Also Published As

Publication number Publication date
WO1999034819A3 (fr) 1999-11-04
JP2002500195A (ja) 2002-01-08
CA2315294A1 (fr) 1999-07-15
DE69813620D1 (de) 2003-05-22
AU1971899A (en) 1999-07-26
ATE237345T1 (de) 2003-05-15
EP1041997A2 (fr) 2000-10-11
FR2773078A1 (fr) 1999-07-02
JP4557421B2 (ja) 2010-10-06
FR2773078B1 (fr) 2000-05-26
DK1041997T3 (da) 2003-08-04
WO1999034819A2 (fr) 1999-07-15
EP1041997B1 (fr) 2003-04-16
DE69813620T2 (de) 2004-02-12
CA2315294C (fr) 2012-07-03

Similar Documents

Publication Publication Date Title
DE60032486D1 (de) Prion protein peptide und deren verwendung
DE69431060D1 (de) Klonierte glutaminsäure-decarboxylase
HUP9802212A2 (hu) Humán terápiában alkalmazható rekombináns anti-CD4-ellenanyagok
SV1998000122A (es) Medicamentos ref. pu 3375/sv
ATE255128T1 (de) Peptid-immitierende substanzen in der krebstherapie
IL96907A0 (en) Proteins produced by human lymphocytes,a dna sequence coding for said proteins and their pharmaceutical and biological application
ES2164914T3 (es) Medicamentos de inmunoterapia que contienen anticuerpos que detectan especificamente el antigeno mhcii del paciente a tratar.
ES2196007T3 (es) Especificidad para peptidos sinteticos de los anti-proteina basica de la mielina procedentes del liquido cefalorraquideo en esclerosis multiple.
ES2193601T3 (es) Utilizacion de peptidos de citrulina derivados a la filagrina en el marco del tratamiento de enfermedades autoinmunes.
ATE534669T1 (de) Verfahren zum erhalten von anti-idiotyp antikörpern
HUP9700676A2 (hu) Rekombináns anti-Fas antitestek és az ezeket kódoló DNS
ZA943920B (en) Pharmaceutical compositions
ATE254595T1 (de) 2-amino-6-methyl-7-acetyl-tetralin und pharmazeutische zusammensetzungen zur vorbeugung und therapeutischen behandlung von entzündlichen und/oder autoimmunkrankheiten
GR3031990T3 (en) Novel peptides for use in treatment of t-cell mediated cartilage destruction in autoimmune diseases
ES2145061T3 (es) Diagnostico y terapia a base de peptidos para el tratamiento de las espondiloartropatias.
ATE163939T1 (de) Peptide und antikörper zur behandlung von rheumatoider arthritis.
ID23184A (id) Garam-garam peptida bpc dengan aktivitas organoprotektif proses pembuatan dan penggunaannya dalam terapi
WO2000005254A3 (en) Novel peptides for use in immunotherapy of autoimmune diseases
NO993684L (no) Peptider som omfatter et T-celle-epitop spesifikt til kollagen-II
PT789761E (pt) Scf humano, uma respectiva variante de processamento, sua utilizacao farmaceutica
NZ505580A (en) Method of treating immunodeficiences using neutrokine alpha
ATE239499T1 (de) Protein-disulfid-isomerasen enthaltende pharmazeutische zusammensetzungen
PT999849E (pt) Utilizacao de lbp no tratamento da septicemia